Chris Viehbacher appointed Sanofi-Aventis CEO

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi-Aventis announced September 10 that Chris Viehbacher will succeed Gerard Le Fur as the company's CEO, effective December 1, 2008. 

The announcement came two days after Viehbacher resigned his postion on GlaxoSmithKline's board, with plans to leave the company entirely. Viehbacher will remain executive director and president at GSK until December 1.

Viehbacher, also a PhRMA board member, was a contender for the CEO position at GSK following the retirement of Jean-Pierre Garnier last May. Andrew Witty, currently the CEO at GSK, secured that postion.

According to a statement from the Sanofi board of directors, Le Fur will stay on at Sanofi after Viehbacher becomes CEO, and will "provide his competences to the general management of the group in the scientific domain." The financial conditions of Viehbacher's hiring will be posted online in the coming days, according to the Sanofi statement. 
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?